|
102 Companies |
|
136 Products |
|
136 Products |
|
123 Mechanisms of Action |
|
5 Trials |
|
1111 News |
|
| «12...345678910111213...1617» |
- | rosuvastatin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke (clinicaltrials.gov) - Nov 20, 2014
P3, N=318, Terminated, Sponsor: Severance Hospital
N=548 --> 318 | Recruiting --> Terminated | Trial primary completion date: Apr 2012 --> Apr 2013; Slow enrollment
- ||| cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Trial primary completion date: Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores (clinicaltrials.gov) - Nov 20, 2014
P2, N=65, Recruiting, Sponsor: Emory University
N=548 --> 318 | Recruiting --> Terminated | Trial primary completion date: Apr 2012 --> Apr 2013; Slow enrollment N=40 --> 65 | Trial primary completion date: Feb 2015 --> Sep 2015
- Trial primary completion date, Surgery: Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study (clinicaltrials.gov) - Nov 19, 2014
P3, N=3302, Recruiting, Sponsor: Regione Emilia-Romagna
N=40 --> 65 | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- |||| omega-3 ethylester concentrate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation (clinicaltrials.gov) - Nov 18, 2014
P4, N=190, Completed, Sponsor: Vanderbilt University
Trial primary completion date: Jun 2015 --> Dec 2015 Active, not recruiting --> Completed | N=450 --> 190 | Trial primary completion date: Nov 2013 --> Apr 2014
- ||| Enrollment change, Trial primary completion date: Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers (clinicaltrials.gov) - Nov 17, 2014
P2, N=85, Recruiting, Sponsor: Emory University
Active, not recruiting --> Completed | N=450 --> 190 | Trial primary completion date: Nov 2013 --> Apr 2014 N=70 --> 85 | Trial primary completion date: Feb 2015 --> Sep 2015
- || Trial primary completion date: SUIVICOL: Prognostic Value of Human Papillomavirus (HPV) Detection in Cervical Intra-epithelial Neoplasia (CIN) Recurrence After Conization (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=300, Recruiting, Sponsor: University Hospital, Bordeaux
N=70 --> 85 | Trial primary completion date: Feb 2015 --> Sep 2015 Trial primary completion date: May 2016 --> Nov 2016
- |||| goserelin acetate / Generic mfg.
Trial primary completion date: ELAAT: Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy (clinicaltrials.gov) - Nov 12, 2014
P3, N=1100, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial primary completion date: May 2016 --> Nov 2016 Trial primary completion date: Jun 2014 --> Dec 2014
- ||||| Stivarga (regorafenib) / Bayer
New P2 trial, Metastases: Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment (clinicaltrials.gov) - Nov 12, 2014
P2, N=80, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- ||||| Trial initiation date, Trial primary completion date: Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance (clinicaltrials.gov) - Nov 7, 2014
P3, N=460, Not yet recruiting, Sponsor: University of Toronto
Trial primary completion date: Jun 2014 --> Dec 2014 Initiation date: Sep 2014 --> Mar 2015 | Trial primary completion date: Aug 2017 --> Aug 2018
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial completion, Trial primary completion date: Herbal Therapy for Treatment of Recurrent Prostate Cancer (clinicaltrials.gov) - Nov 5, 2014
P2, N=43, Completed, Sponsor: University of Southern California
Initiation date: Sep 2014 --> Mar 2015 | Trial primary completion date: Aug 2017 --> Aug 2018 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014
- escitalopram / Generic mfg.
Trial primary completion date, Head-to-Head: Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial (clinicaltrials.gov) - Nov 4, 2014
P3, N=240, Recruiting, Sponsor: University of Sao Paulo
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jul 2014 Trial primary completion date: Oct 2017 --> Jan 2017
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Enrollment open: DAFNE: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=300, Recruiting, Sponsor: Astellas Pharma S.A.S.
Trial primary completion date: Oct 2017 --> Jan 2017 Not yet recruiting --> Recruiting
- ||| esomeprazole / Generic mfg.
Trial completion: Nexium Capsules RE Maintenance Specific Clinical Experience Investigation (clinicaltrials.gov) - Oct 31, 2014
P=N/A, N=647, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P1 trial: EPSITCRYSP: Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol (clinicaltrials.gov) - Oct 30, 2014
P1, N=23, Completed, Sponsor: Ankara University
- ||| Enrollment closed, Trial primary completion date: Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy (clinicaltrials.gov) - Oct 30, 2014
P4, N=1080, Active, not recruiting, Sponsor: Qidong Gaitianli Medicines Co., Ltd
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2014 --> May 2016
- | Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
New P1 trial: Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 (clinicaltrials.gov) - Oct 22, 2014
P1, N=48, Recruiting, Sponsor: Luye Pharma Group Ltd.
- Trial completion: Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=25, Completed, Sponsor: Ain Shams University
Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2014 --> May 2016 Active, not recruiting --> Completed
- | New P1 trial: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (clinicaltrials.gov) - Oct 10, 2014
P1, N=48, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- Enrollment change, Trial primary completion date: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=150, Recruiting, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=202 --> 150 | Trial primary completion date: Jul 2014 --> Feb 2015
- || New P3 trial: POPCUR: Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease (clinicaltrials.gov) - Oct 2, 2014
P3, N=122, Not yet recruiting, Sponsor: University Hospital, Clermont-Ferrand
- | azathioprine / Generic mfg.
New P2 trial: Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. (clinicaltrials.gov) - Sep 28, 2014
P2, N=63, Terminated, Sponsor: Universitaire Ziekenhuizen Leuven
- cisplatin / Generic mfg., sirolimus / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Surgery: Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery (clinicaltrials.gov) - Sep 15, 2014
P1, N=13, Recruiting, Sponsor: Mayo Clinic
N=202 --> 150 | Trial primary completion date: Jul 2014 --> Feb 2015 Trial primary completion date: Sep 2014 --> Dec 2014
- Biomarker, Enrollment closed, Trial primary completion date, Surgery: Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery (clinicaltrials.gov) - Sep 15, 2014
P2, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015
- |||||||||| VivaGel (astodrimer vaginal) / Starpharma
New P3 trial: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Sep 10, 2014
P3, N=620, Recruiting, Sponsor: Starpharma Pty Ltd
- ||| Enrollment open, Trial primary completion date: The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence (clinicaltrials.gov) - Sep 10, 2014
P=N/A, N=80, Recruiting, Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Sep 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Feb 2016
- Clinical: The Factors Associated With the Recurrence in Patients With Cushing Disease (clinicaltrials.gov) - Sep 8, 2014
P=N/A, N=42, Completed, Sponsor: National Taiwan University Hospital
- Trial primary completion date: Monitor-AF;EPEUHM: Management of New-Onset Postoperative Atrial Fibrillation (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=50, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2015 --> Feb 2016 Trial primary completion date: Oct 2014 --> Oct 2016
- Trial primary completion date: PseudIgY: Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis (clinicaltrials.gov) - Sep 5, 2014
P1/2, N=20, Active, not recruiting, Sponsor: Immunsystem AB
Trial primary completion date: Oct 2014 --> Oct 2016 Trial primary completion date: Dec 2014 --> Dec 2018
- || Votrient (pazopanib) / Novartis, BeiGene
Biomarker: Neoadjuvant Pazopanib in Renal Cell Carcinoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=56, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2018 Trial primary completion date: Jun 2014 --> Jun 2016
- ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Trial primary completion date: DIGNITY: Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall (clinicaltrials.gov) - Sep 4, 2014
P1/2, N=20, Recruiting, Sponsor: Celsion
Trial primary completion date: Jun 2014 --> Jun 2016 Trial primary completion date: Sep 2014 --> Jun 2015
- Urocidin (mycobacterium cell wall-DNA complex) / Liminal BioSci
Enrollment change: First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC (clinicaltrials.gov) - Aug 29, 2014
P3, N=0, Withdrawn, Sponsor: Bioniche Life Sciences Inc.
Trial primary completion date: Sep 2014 --> Jun 2015 N=811 --> 0
- paclitaxel / Generic mfg.
Enrollment open, Trial initiation date: Reirradiation With Concurrent Paclitaxel for Breast Cancer (clinicaltrials.gov) - Aug 28, 2014
P1, N=18, Recruiting, Sponsor: University of Kentucky
N=811 --> 0 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014
- | Enrollment open, Trial primary completion date: The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy (clinicaltrials.gov) - Aug 28, 2014
P3, N=182, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Jul 2014 Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2013 --> Jan 2015
- || New P2/3 trial: Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence (clinicaltrials.gov) - Aug 27, 2014
P2/3, N=200, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial completion: Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases (clinicaltrials.gov) - Aug 27, 2014
P2, N=10, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2013 --> Jan 2015 Active, not recruiting --> Completed
- Enrollment closed: ARMCENVIN: Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=216, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment open, Trial primary completion date: Long-term Follow-up After Laparoscopic Inguinal Hernia Repair Using Tisseel for Mesh Fixation (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=2340, Recruiting, Sponsor: Herlev Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Sep 2014
- Trial completion, Enrollment change, Trial primary completion date, HEOR, Adherence: Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients (clinicaltrials.gov) - Aug 21, 2014
P2, N=40, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Sep 2014 Recruiting --> Completed | N=50 --> 40 | Trial primary completion date: Dec 2012 --> May 2014
- | amiodarone / Generic mfg.
Trial completion: SPECULATE: Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation (clinicaltrials.gov) - Aug 21, 2014
P3, N=176, Completed, Sponsor: Texas Cardiac Arrhythmia Research Foundation
Recruiting --> Completed | N=50 --> 40 | Trial primary completion date: Dec 2012 --> May 2014 Recruiting --> Completed
- |||| Dexilant (dexlansoprazole) / Takeda
Enrollment open: Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation (clinicaltrials.gov) - Aug 19, 2014
P4, N=150, Recruiting, Sponsor: Takeda
Recruiting --> Completed Not yet recruiting --> Recruiting
- everolimus / Generic mfg.
Trial primary completion date: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (clinicaltrials.gov) - Aug 15, 2014
P3, N=40, Recruiting, Sponsor: Hospital Vall d'Hebron
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2013 --> Nov 2015
- Dificid (fidaxomicin) / Merck (MSD), Astellas
Clinical: DAFNE: Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=300, Not yet recruiting, Sponsor: Astellas Pharma S.A.S.
- Trial completion: APPRAISE: Atrial Electromechanical Interval and Pulse Wave Velocity in the Prediction of Recurrence of Atrial Fibrillation (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=129, Completed, Sponsor: Creighton University
Trial primary completion date: Nov 2013 --> Nov 2015 Recruiting --> Completed
- |||| Serlipet (piboserod) / GSK, Serodus
Trial completion: Prevention Of Recurrence Of Atrial Fibrillation (clinicaltrials.gov) - Aug 11, 2014
P2, N=520, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- | Multaq (dronedarone) / Sanofi
Trial termination: ELECTRAt: Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA) (clinicaltrials.gov) - Aug 6, 2014
P4, N=292, Terminated, Sponsor: Sanofi
Active, not recruiting --> Completed Completed --> Terminated; 'Sponsor decision following recruitment issues, not related to any safety concerns in the study
- Trial termination, Surgery, Biopsy: Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA (clinicaltrials.gov) - Aug 5, 2014
P2, N=2, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Completed --> Terminated; 'Sponsor decision following recruitment issues, not related to any safety concerns in the study Completed --> Terminated; low accrual
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg.
Metastases: Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=30, Recruiting, Sponsor: National Taiwan University Hospital
- Enrollment change: Atrial Fibrillation Recurrence in Sleep Apnea (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=25, Completed, Sponsor: Mayo Clinic
Completed --> Terminated; low accrual N=196 --> 25
- azacitidine / Generic mfg.
New P2 trial: UPCI 13-165: Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS (clinicaltrials.gov) - Jul 30, 2014
P2, N=35, Not yet recruiting, Sponsor: University of Pittsburgh
- | sirolimus / Generic mfg.
Trial completion: Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 30, 2014
P3, N=525, Completed, Sponsor: University of Regensburg
N=196 --> 25 Active, not recruiting --> Completed